Latest Breaking News On - நிக்கோல் டோரியா உயர்ந்தது - Page 2 : comparemela.com
Moderna COVID-19 vaccine protection lasts at least 6 months, study finds
q13fox.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q13fox.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Madan, a postdoctoral researcher in the DeKosky lab at the University of Kansas School of Pharmacy, headed research into potential of the vFP16.02 antibody view more
Credit: Matheus Oliveira de Souza
LAWRENCE Much like coronavirus, circulating HIV-1 viruses mutate into diverse variants that pose challenges for scientists developing vaccines to protect people from HIV/AIDS. AIDS vaccine development has been a decades-long challenge partly because our immune systems have difficulty recognizing all the diverse variants of the rapidly mutating HIV virus, which is the cause of AIDS, said Brandon DeKosky, assistant professor of pharmaceutical chemistry and chemical & petroleum engineering at the University of Kansas.
Thu, 03/11/2021
LAWRENCE Much like coronavirus, circulating HIV-1 viruses mutate into diverse variants that pose challenges for scientists developing vaccines to protect people from HIV/AIDS.
“AIDS vaccine development has been a decades-long challenge partly because our immune systems have difficulty recognizing all the diverse variants of the rapidly mutating HIV virus, which is the cause of AIDS,” said Brandon DeKosky, assistant professor of pharmaceutical chemistry and chemical & petroleum engineering at the University of Kansas.
In the past five years, tremendous progress has been made in identifying better vaccine methods to protect against many different HIV-1 variants. One important step was when scientists at the National Institute of Allergy and Infectious Disease’s Vaccine Research Center discovered a promising antibody called vFP16.02. Antibodies are proteins the immune system deploys to target and destroy pathogens and viruses and scientists at the NIH determ
To revist this article, visit My Profile, then View saved stories.
A year ago, in January, when John Mascola heard that a new coronavirus had been detected in an animal market in Wuhan, China, he left everything at his desk on the fourth floor of the US government’s Vaccine Research Center and walked up one flight of stairs to the office of a longtime colleague, Nicole Doria-Rose. Felicitously, Mascola, who is the center’s director, had been working on ways to immunize people against coronaviruses. A vaccine against this new bug, soon to be known as SARS-CoV-2, was the first priority, the only surefire way of halting the growing pandemic. Mascola and Doria-Rose, an immunologist, go way back. And they hoped there was another approach that might also contribute to the cause, one they’d been chasing for more than a decade. They wanted to find a monoclonal antibody.
vimarsana © 2020. All Rights Reserved.